drugset / Trial / NCT00420043

Effect of Food on Bioavailability of Modified Release Formulations of Imatinib

NCT00420043

Phase 1 Completed 32 enrolled Novartis
RandomizedCrossoverOpen-labelTreatment

Summary

This study will evaluate the effect of food on the relative bioavailability of a single dose of imatinib given as a 800 mg modified release tablet, compared to twice-daily doses of 400 mg film-coated tablets. There will be a 8 day wash out phase between treatments and a 1 week safety period at the end of the study. Each participant will receive all four treatments.

Timeline

Start
2006-09
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 400 mg
Subject Imatinib Small molecule 800 mg

Indications

No indication recorded.